Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men

Prostate Cancer and Prostatic Diseases volume 13, pages 94–96 (2010)Cite this article

Abstract

Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells. A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients. DNA was extracted from the blood drawn from 399 prostate cancer patients, 150 BPH patients and 294 healthy community controls. Polymerase chain reaction was carried out and single nucleotide polymorphisms of FGFR4 were identified by restriction enzyme digestion. No overall association is detectable between the Arg allele and increased prostate cancer risk. Subgroup analysis shows a higher incidence of the heterozygous ArgGly genotype in cancer cases than in the combined group of BPH and controls (P<0.05); this difference is statistically significant between cancer and BPH patients but not between cancer cases and community controls. The single nucleotide polymorphism Gly388Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men. This observation is in contrast with results from two previous studies conducted in the USA and Japan.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. NHS Scotland Information Services Division. Cancer in Scotland. 2008.

  2. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ . Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007; 213: 82–90.

    Article  CAS  PubMed  Google Scholar 

  3. Wilkie AO, Morriss-Kay GM, Jones EY, Heath JK . Functions of fibroblast growth factors and their receptors. Curr Biol 1995; 5: 500–507.

    Article  CAS  PubMed  Google Scholar 

  4. Eswarakumar VP, Lax I, Schlessinger J . Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139–149.

    Article  CAS  PubMed  Google Scholar 

  5. Wang J, Stockton DW, Ittmann M . The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004; 10 (18 Part 1): 6169–6178.

    Article  CAS  PubMed  Google Scholar 

  6. Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer 2008; 123: 2574–2579.

    Article  CAS  PubMed  Google Scholar 

  7. Binnie MC, Alexander FE, Heald C, Habib FK . Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. Prostate 2005; 63: 309–315.

    Article  CAS  PubMed  Google Scholar 

  8. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002; 62: 840–847.

    CAS  PubMed  Google Scholar 

  9. Bland JM, Altman DG . Statistics notes. The odds ratio. BMJ 2000; 320: 1468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. da Costa Andrade VC, Parise Jr O, Hors CP, de Melo Martins PC, Silva AP, Garicochea B . The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007; 82: 53–57.

    Article  PubMed  Google Scholar 

  11. Hsing AW, Tsao L, Devesa SS . International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60–67.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from Cancer Research UK. We thank Margaret Binnie for her technical assistance.

Author information

Authors and Affiliations

  1. Prostate Research Group, The Chancellors Building, University of Edinburgh, Edinburgh, UK

    C K M Ho, J Nanda & F K Habib

  2. Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, UK

    C K M Ho & S Anwar

Authors
  1. C K M Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Anwar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Nanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F K Habib
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F K Habib.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ho, C., Anwar, S., Nanda, J. et al. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men. Prostate Cancer Prostatic Dis 13, 94–96 (2010). https://doi.org/10.1038/pcan.2009.49

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.49

Keywords

This article is cited by

Search

Advanced search

Quick links